Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal...

Related Keywords

Australia ,Berlin ,Germany ,Russia ,Ukraine ,Ohio ,United States ,Cleveland ,German ,Richard Rudick ,Josepha Murray ,Paula Schwartz ,Edna Kaplan ,Robertj Fox ,Jessica Breu ,Vincent Ossipow ,Michael Schumann ,Daniel Vitt ,Americas Committee For Treatment ,Rx Communications Group ,Exchange Commission ,Mellen Center ,Development Rd Expenses ,Immunic Inc ,Nasdaq ,Research In Multiple Sclerosis ,Neurologic Institute ,Positive Results From Phase ,Clinical Trial ,Celiac Disease Provide Proof Of Concept ,New Therapeutic Approach ,Treat Gastrointestinal Diseases ,Promoting Regeneration ,Bowel Architecture ,Interim Results From Phase ,Vidofludimus Calcium ,Progressive Multiple Sclerosis Expected ,Second Half ,Cash Equivalents ,Investments Expected ,Fund Immunic Into ,Fourth Quarter ,Held Today ,Chief Executive Officer ,Digestive Disease Week ,Strengthened Board ,Staff Neurologist ,Multiple Sclerosis ,Cleveland Clinic ,Americas Committee ,Mayo Clinic ,German Federal Ministry ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,Consolidated Statements ,Immunic ,Nc ,